GlassScriptPhysician profile
Emily Miller
NPI 1528396207
$8,383.44
in general payments reported to CMS, 2019-2025
24 companies · $1,439 in 2025
The $1,439 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $702 · 2022: $1,373 · 2023: $1,988 · 2024: $2,883 · 2025: $1,439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,003 · Consulting Fee: $1,063 · Education: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,003.41 |
| Consulting Fee | $1,062.50 |
| Education | $242.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,398.96 | 2021-2025 | Tremfya |
| Abbvie INC. | $2,156.87 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $751.57 | 2021-2025 | |
| Genzyme Corporation | $509.62 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $441.47 | 2023-2025 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $396.17 | 2022-2024 | Spevigo |
| Sun Pharmaceutical Industries INC. | $302.93 | 2021-2025 | |
| Amgen INC. | $259.42 | 2021-2024 | Otezla |
| Lilly USA, LLC | $209.65 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $202.98 | 2022-2025 | Dupixent, Libtayo |
| Pfizer INC. | $147.03 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $140.65 | 2025 | |
| Janssen Scientific Affairs, LLC | $75.16 | 2022 | |
| Incyte Corporation | $58.15 | 2023-2024 | Opzelura |
| Almirall LLC | $56.44 | 2021-2024 | Klisyri |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $55.90 | 2021-2025 | Nemluvio, Aklief |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $48.58 | 2023-2025 | Cabtreo, Jublia |
| Arcutis Biotherapeutics, INC. | $43.14 | 2024-2025 | Zoryve |
| Ucb, INC. | $32.49 | 2025 | Bimzelx |
| Leo Pharma INC. | $29.20 | 2022-2025 | Anzupgo |
| Next Science LLC | $20.00 | 2023 | Xperience, Blastx, Surgx |
| Vyne Pharmaceuticals INC. | $18.49 | 2021 | |
| Biosense Webster, INC. | $14.42 | 2025 | Soundstar, Nuvision Ice Catheter |
| Verrica Pharmaceuticals INC. | $14.15 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.